Vantage Health and its parent company Nanobeak announced that they have formed a strategic partnership with Scripps Translational Science Institute (STSI) for the advancement of mobile health technology.
With its foundations in advanced nanotechnology, Vantage’s first product, the Health Sensor, is the convergence of nanoelectronics, bioinformatics and wireless technology to create the next-generation mobile health application.
The company’s first mobile app is expected to be for lung cancer screening, with additional mobile health care apps in the planning stages.
STSI and Vantage Health plan to collaborate on the planning and execution of clinical trials. The actual clinical trials are expected to be carried out at STSI, as well as a second location in the Midwest and a third location in New England.
Through this strategic partnership, STSI will assist in the testing, evaluation and detection of certain basic volatile organic compounds (VOCs) using gas chromatography and mass spectrometry to calibrate the results of the Vantage sensor through validation.
“This is arguably one of the most vital and exciting steps in our effort to transfer the technology out of the labs at NASA and into the marketplace, as part of our commercialization process,” Jeremy Barbera, chairman and CEO of Vantage Health, said in a statement. “STSI’s Center for Digital Medicine, under the leadership of STSI Director Eric Topol, M.D., and Scripps Health digital medicine Director Steven Steinhubl, M.D., brings to Vantage the expertise and clinical trial experience necessary to successfully advance our mobile health applications.”
Vantage Health is developing personalized and point-of-care screening using apps based upon chemical sensing residing within a small device attached to a smartphone, while STSI’s Center for Digital Medicine works to further the development and research of novel mobile health devices to accelerate their uptake into clinical practice.
“This kind of collaboration is essential for the testing and validation of wireless and mobile health technologies. It offers the chance for transformational changes in the way we diagnose and treat a wide range of conditions,” Steinhubl said in a statement.
STSI is a National Institutes of Health-sponsored consortium led by Scripps Health in collaboration with The Scripps Research Institute. Through this partnership, STSI is heading the effort to translate the latest wireless and genetic medical technologies into more cost-effective treatments for patients.
Scripps Health is an integrated not-for-profit health system based in San Diego, with five hospital campuses and 26 outpatient clinics.